Latex (natural rubber latex) allergy
Occupational / perioperative allergy · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Two distinct reactions to natural rubber latex: immediate IgE-mediated (type I, Hevea proteins; urticaria → anaphylaxis) and delayed type IV contact dermatitis (to rubber accelerator chemicals). All sensitised patients need latex-safe precautions. High-risk groups: healthcare workers, spina bifida / multiple surgeries, atopic patients, certain occupations. DRAFT for clinician review.
Red flags
- Intraoperative/periprocedural hypotension or bronchospasm of unknown cause (consider latex), especially in spina bifida, multiple-surgery or healthcare-worker patients
- Progressive urticaria/angioedema/airway involvement after latex contact
Assessment
Differential diagnosis
- Type I: other causes of anaphylaxis / contact urticaria; perioperative anaphylaxis from another agent
- Type IV: allergic contact dermatitis to accelerators; irritant contact dermatitis from glove occlusion/handwashing
- Latex-fruit syndrome (banana, kiwi, avocado, chestnut cross-reactivity)
Investigations
- History of reactions temporally linked to latex (gloves, balloons, condoms, dental dams, catheters)
- US: serum latex-specific IgE (only FDA-cleared test; no skin-test extract available in US)
- Europe: skin-prick extract available
- Patch testing to distinguish type IV contact dermatitis
Management
- Acute type I reaction/anaphylaxis — treat per anaphylaxis protocol AND remove the latex source
- Establish a latex-SAFE environment (non-latex/synthetic gloves, latex-free equipment, 'one-stick rule' through latex vial stoppers)
- Flag the chart and apply an allergy band
- Counsel avoidance of latex-containing products and cross-reactive foods
- Prescribe epinephrine autoinjector for type-I patients
- Refer to allergy / occupational health
Drugs & doses
Acute type I reaction / anaphylaxis — treat per anaphylaxis protocol (IM epinephrine) and remove latex. Self-injectable epinephrine for all with a history of systemic reaction.
Type IV contact dermatitis — avoidance + topical corticosteroid (per contact dermatitis management); prescription mupirocin if a topical antibiotic is needed and there is bacitracin/neomycin co-allergy.
No effective preventive pharmacotherapy; immunotherapy and anti-IgE are investigational and not routine.
Disposition
After a systemic reaction — observe, then discharge with epinephrine autoinjector + action plan, medical-alert bracelet, latex-avoidance advice (including pre-procedure notification) and allergy referral. Contact dermatitis — avoidance + topical steroid, dermatology/occupational-health referral.
Complications & pitfalls
- Anaphylaxis (including perioperative/IV exposure via latex vial stoppers)
- Occupational asthma/rhinoconjunctivitis from aerosolised glove powder
- Chronic hand contact dermatitis
- Latex-fruit cross-reactive food anaphylaxis
- Resensitisation with ongoing exposure
Exam pearls
- Manage ALL latex-sensitised patients (even those who had only contact dermatitis) as at risk for type I reactions
- Goal is latex-'safe', not 'latex-free' (a completely latex-free environment is not achievable)
- Injection through a latex vial stopper can trigger reactions in the highly allergic — use synthetic-stopper vials or the 'one-stick rule'
- Cross-reactive foods: banana, kiwi, avocado, chestnut, papaya, potato, tomato
- Latex-specific IgE can persist ≥5 years — continue precautions even if later testing is negative
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.